{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-26-000002","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2026-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.972440+00:00","generated_at":"2026-05-16T09:22:00.091715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46","bullets":["Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).","Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.","Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).","R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.","MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-26-000002","json":"https://secwatch.observer/filing/0000200406-26-000002.json","markdown":"https://secwatch.observer/filing/0000200406-26-000002.md","text":"https://secwatch.observer/filing/0000200406-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/0000200406-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/jnj-20260121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:22:00.091715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}